fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ..... on the right formulation while Mylan has had the generic market to itself. We knew Mylan would eventually face this competition
Mylan ’s reported fourth-quarter results of ..... management’s outlook for the year. We think Mylan ’s narrow economic moat remains intact ..... skeptical of certain products in the pipeline, Mylan ’s ability to launch certain generic
March 2 (Reuters) - U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week.
March 2 (Reuters) - Generic and specialty drugmaker Mylan Inc reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America.
Feb 2 (Reuters) - Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of...
Feb 2 (Reuters) - Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses to expand its line of women's health products.
BRUSSELS, Jan 28 (Reuters) - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by...
as a smaller player within the generics space, doesn't have the scale to compete with giants such as Teva TEVA and Mylan MYL . The stock's valuation isn't attractive, either, trading well above Krempa's $72 fair value estimate. Royal
changes to our fair value estimate for Mylan even after the company's reported ..... moderately surpassed our expectations. Mylan also benefited from some nonrecurring ..... over quality-control issues during Mylan 's acquisition of that firm's Agila
deteriorating pricing will likely remove some biosimilar threats to Lantus over the long term. We believe both Merck and Mylan will reevaluate launching biosimilars. Nevertheless, Lilly's biosimilar will likely still reach the market in Europe